Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH 1

Neoplasia

Volumn 8, Issue 2, 2006, Pages 96-103

  Taraboletti, Giulia ^a   D'Ascenzo, Sandra ^b   Giusti, Ilaria ^b   Marchetti, Daniela ^b   Borsotti, Patrizia ^a   Millimaggi, Danilo ^b   Giavazzi, Raffaella ^a   Pavan, Antonio ^b   Dolo, Vincenza ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Ovarian cancer; pH; Shed membrane vesicles; Tumor angiogenesis; VEGF

Indexed keywords

ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BIOAVAILABILITY; CARCINOMA CELL; CELL INVASION; CELL MOTILITY; CELL STIMULATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE VESICLE; MICROENVIRONMENT; MOLECULAR CLONING; OVARY CARCINOMA; PH; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; TUMOR CELL; WESTERN BLOTTING;

EID: 33646420333     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05583     Document Type: Article

References (37)

1. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31.
2. Carmeliet P and Jain RK (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
3. Bergers G and Benjamin LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3, 401-410.
4. Ferrara N, Gerber HP, and LeCouter J (2003). The biology of VEGF and its receptors. Nat Med 9, 669-676.
5. Dvorak HF (2003). Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol 162, 1747-1757.
6. Hicklin DJ and Ellis LM (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23, 1011-1027.
7. Taylor DD and Black PH (1986). Shedding of plasma membrane fragments. In Steinberg, M (Ed.), Developmental Biology, pp. 33-57 Plenum Press, New York.
8. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, and Dolo V (2002). Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 160, 673-680.
9. Dolo V, Adobati E, Canevari S, Picone MA, and Vittorelli ML (1995). Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens. Clin Exp Metastasis 13, 277-286.
10. Dolo V, Ginestra A, Ghersi G, Nagase H, and Vittorelli ML (1994). Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities. J Submicrosc Cytol Pathol 26, 173-180.
11. Albanese J, Meterissian S, Kontogiannea M, Dubreuil C, Hand A, Sorba S, and Dainiak N (1998). Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles. Blood 91, 3862-3874.
12. 3H-thymidine incorporation, are neutralised by anti TGF-beta antibodies. J Submicrosc Cytol Pathol 27, 535-541.
13. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, et al. (2002). Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360, 295-305.
14. Zitvogel L, Fernandez N, Lozier A, Wolfers J, Regnault A, Raposo G, and Amigorena S (1999). Dendritic cells or their exosomes are effective biotherapies of cancer. Eur J Cancer 35 (Suppl 3), S36-S38.
15. Dolo V, D'Ascenzo S, Violini S, Pompucci L, Festuccia C, Ginestra A, Vittorelli ML, Canevari S, and Pavan A (1999). Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells teinases in vivo and in vitro vitro. Clin Exp Metastasis 17, 131-140.
16. Dolo V, Ginestra A, Cassara D, Violini S, Lucania G, Torrisi MR, Nagase H, Canevari S, Pavan A, and Vittorelli ML (1998). Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res 58, 4468-4474.
17. Ginestra A, Monea S, Seghezzi G, Dolo V, Nagase H, Mignatti P, and Vittorelli ML (1997). Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem 272, 17216-17222.
18. Angelucci A, D'Ascenzo S, Festuccia C, Gravina GL, Bologna M, Dolo V, and Pavan A (2000). Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clin Exp Metastasis 18, 163-170.
19. Poste G and Nicolson GL (1980). Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells. Proc Natl Acad Sci USA 77, 399-403.
20. Shedden K, Xie XT, Chandaroy P, Chang YT, and Rosania GR (2003). Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res 63, 4331-4337.
21. Taverna S, Ghersi G, Ginestra A, Rigogliuso S, Pecorella S, Alaimo G, Saladino F, Dolo V, Dell'Era P, Pavan A, et al. (2003). Shedding of membrane vesicles mediates fibroblast growth factor-2 release from cells. J Biol Chem 278, 51911-51919.
22. Kim CW, Lee HM, Lee TH, Kang C, Kleinman HK, and Gho YS (2002). Extracellular membrane vesicles from tumor cells promote angiogenesis genesis via sphingomyelin. Cancer Res 62, 6312-6317.
23. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, and Ratajczak MZ (2005). Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 113, 752-760.
24. Dolo V, Ginestra A, Violini S, Miotti S, Festuccia C, Miceli D, Migliavacca M, Rinaudo C, Romano FM, Brisdelli F, et al. (1997). Ultrastructural and phenotypic characterization of CABA I, a new human ovarian cancer cell line. Oncol Res 9, 129-138.
25. Manenti L, Riccardi E, Marchini S, Naumova E, Floriani I, Garofalo A, Dossi R, Marazzo E, Ribatti D, Scanziani E, et al. (2005). Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther 4, 715-725.
26. Taraboletti G, Roberts D, Liotta LA, and Giavazzi R (1990). Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 111, 765-772.
27. Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, and Cherrington JM (2000). The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 6, 4848-4858.
28. Sidhu SS, Mengistab AT, Tauscher AN, LaVail J, and Basbaum C (2004). The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions. Oncogene 23, 956-963.
29. 2 gradients in solid tumors in vivo vivo: high-resolution measurements : reveal a lack of correlation. Nat Med 3, 177-182.
30. Gatenby RA and Gillies RJ (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4, 891-899.
31. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, and Whiteside TL (2005). Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 11, 1010-1020.
32. Zucker S, Wieman JM, Lysik RM, Wilkie DP, Ramamurthy N, and Lane B (1987). Metastatic mouse melanoma cells release collagen-gelatin degrading metalloproteinases as components of shed membrane vesicles. Biochim Biophys Acta 924, 225-237.
33. Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, and Mor G (2003). Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 63, 5573-5581.
34. Martinez-Lorenzo MJ, Anel A, Alava MA, Pineiro A, Naval J, Lasierra P, and Larrad L (2004). The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res 295, 315-329.
35. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, and Surprenant A (2001). Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 15, 825-835.
36. Xu L and Fidler IJ (2000). Acidic pH- induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res 60, 4610-4616.
37. Pugh CW and Ratcliffe PJ (2003). Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9, 677-684.